Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Share-based Compensation (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Share-based Compensation readings, the most recent being $1.5 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 14.49% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 40.31% decrease, with the full-year FY2025 number at $5.0 million, down 40.32% from a year prior.
  • Share-based Compensation hit $1.5 million in Q4 2025 for Aligos Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q2 2022 to a low of $959000.0 in Q1 2025.
  • Median Share-based Compensation over the past 5 years was $3.2 million (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Share-based Compensation: increased 15.84% in 2022 and later plummeted 63.78% in 2025.
  • Aligos Therapeutics' Share-based Compensation stood at $3.7 million in 2021, then dropped by 6.44% to $3.4 million in 2022, then decreased by 24.39% to $2.6 million in 2023, then plummeted by 33.99% to $1.7 million in 2024, then decreased by 14.49% to $1.5 million in 2025.
  • The last three reported values for Share-based Compensation were $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.